Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2025—For Neisseria gonorrhoeae, the pipeline of antibiotics is running dry, and antimicrobial resistance is a global threat. “It’s just a matter of when it’s going to happen,” says Olusegun O. Soge, PhD, MSc, associate professor of global health and of medicine and adjunct associate professor of laboratory medicine and pathology at the University of Washington.
April 2025—Cancer claims about 10 million lives every year. It is the second leading cause of death in the U.S., according to the American Cancer Society. On World Cancer Day in February, these sobering statistics served as a powerful reminder of the scale of the disease’s impact and how it touches all our lives, directly or indirectly. And with cancer incidence set to rise dramatically, the fight is far from over. The World Health Organization predicts a 60 percent rise in cancer cases globally in the next 20 years, driven by a combination of risk factors. In parallel, health systems are struggling to cope with an aging population, and we see uneven access across the globe to the quality health care that gives the best chance at survival.
April 2025—Unprecedented moves with a lot of moving parts is how Jessica Wang-Rodriguez, MD, of the Veterans Health Administration describes a transition to digital pathology the size of the VHA’s. It’s a mission that has become necessary, Dr. Wang-Rodriguez says of the large-scale digital pathology transformation. She is executive director of the VHA National Pathology and Laboratory Medicine Program Office, Washington, DC, and professor of pathology at the University of California, San Diego.
April 2025—A few years after its launch, the CAP’s online Interactive Surgical Pathology Cases webinar series is set to roll out for this year, with a session on urinary bladder pathology to take place May 14. The faculty members for the two-hour session are Lara Harik, MD, of Emory University School of Medicine, and Sara E. Wobker, MD, MPH, of UNC School of Medicine. The focus will be common diagnostic pitfalls in flat and papillary urinary bladder cases and a practical approach to diagnosing and grading such cases. The second online session, on head and neck pathology, will take place Aug. 28, and the third, on lung pathology, is scheduled for Nov. 12. All begin at noon central time. The second and third sessions this year will be one hour.
April 2025—Rebecca Previs, MD, MS, gynecologic oncologist and director of medical affairs at Labcorp, captures the vibe ahead of the ASCO conference next month in Chicago in just a few words. “It’s exciting,” she says. “This is unprecedented territory.” With the field undergoing “a major shift toward biology-driven rather than tissue-of-origin-driven oncology treatment,” Dr. Previs is far from the only industry representative who is optimistic about the future—though the many challenges ahead temper that excitement.
April 2025—Payer policy changes—“It’s almost impossible for the provider community to keep up,” Harley Ross of XiFin said in a Feb. 14 online roundtable led by CAP TODAY publisher Bob McGonnagle. Ross and five other experts in pathology and laboratory medicine billing talked about prior authorizations, denials, narrow networks, and the need to advocate for laboratories.
April 2025—CAP TODAY publisher Bob McGonnagle spoke with Anthony Alburo, MBA, market development manager, diagnostics, Tosoh Bioscience, Melanie Samko, director of marketing, Tosoh Bioscience, and Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare. Anthony Alburo opens the conversation.
Anthony Alburo: Tosoh Bioscience has a longstanding legacy in immunoassay diagnostics and HPLC [high-performance liquid chromatography] technology. Our immunoassay platforms support comprehensive cancer care with reimbursable tests for oncology, endocrinology, reproductive health, and chronic disease management. Our HPLC column solution has set the standard in A1C testing, a key factor in managing diabetes, which can intersect with cancer treatment. We remain committed to advancing laboratory science to support clinicians and patients at every stage of care.
I’m honored to introduce Melanie Samko, our director of marketing, who brings not only a deep expertise in health care marketing but also a deep personal perspective: She is a breast cancer survivor. Her journey highlights the real-world impact of early detection, diagnostic accuracy, and patient advocacy. Carrie Pruett, MLS(ASCP)CM, laboratory quality and compliance manager at Illinois CancerCare, which recently merged with the US Oncology Network, has extensive expertise in laboratory operations and compliance. She will provide invaluable insights into the challenges and advancements in oncology diagnostics. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by Tosoh Bioscience in recognition of National Cancer Prevention Month.
March 2025—Like an inspired Adam in the Garden of Eden, molecular experts have been busy with the naming process as it applies to liquid biopsy. It’s lost to the myths of time whether Adam revised his nomenclature, but pathologists and other experts are eager to identify new assays as they push this field forward, from circulating cell-free DNA to circulating tumor DNA to circulating tumor RNA. Soon another assay, one that combines ctDNA and ctRNA, could begin to make its mark as well, says Keyur P. Patel, MD, PhD, medical director of the molecular diagnostics laboratory, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center. He and his colleagues plan to launch an assay to look for circulating total nucleic acid. “DNA plus RNA equals TNA—that’s the mathematical equation,” jokes Dr. Patel, who is also professor, Department of Hematopathology, Division of Pathology and Laboratory Medicine. And like that first zookeeper, there’s even an actual beast for experts to name.
March 2025—Theresa Kinard, MD, knew little about phosphatidylethanol (PEth), a blood-based biomarker of alcohol use, when she noticed that patients who adamantly denied drinking were testing positive in their liver pretransplant evaluations.
March 2025—The Ventana CLDN18 (43-14A) RxDx Assay, the companion diagnostic for zolbetuximab, detects the claudin 18 protein in formalin-fixed, paraffin-embedded gastric adenocarcinoma including gastroesophageal junction tissue specimens. Gastric intestinal metaplasia can be used as a positive tissue control and system level control and should display weak to moderate membrane staining.
